Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.

[1]  J. Rae,et al.  Metabolism of N,N′,N″-Triethylenethiophosphoramide by CYP2B1 and CYP2B6 Results in the Inactivation of Both Isoforms by Two Distinct Mechanisms , 2004, Journal of Pharmacology and Experimental Therapeutics.

[2]  M. Eichelbaum,et al.  Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine , 2004, Journal of Pharmacology and Experimental Therapeutics.

[3]  P. Beaune,et al.  Induction of Cytochrome P450 2B6 and 3A4 Expression by Phenobarbital and Cyclophosphamide in Cultured Human Liver Slices , 2003, Pharmaceutical Research.

[4]  Steven J M Jones,et al.  Influence of scheduling on two-drug combinations of alkylating agents in vivo , 2004, Cancer Chemotherapy and Pharmacology.

[5]  C. Vecht,et al.  Interactions between antiepileptic and chemotherapeutic drugs , 2003, The Lancet Neurology.

[6]  G. Ferron,et al.  Quantitation of cytochrome P450 mRNA levels in human skin. , 2003, Analytical biochemistry.

[7]  U. Yasar,et al.  Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation , 2003, The Pharmacogenomics Journal.

[8]  D. Flockhart,et al.  Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[9]  A. Birnbaum,et al.  Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA , 2002, Cancer Chemotherapy and Pharmacology.

[10]  S. Hall,et al.  Mechanism-Based Inhibition of Human Cytochromes P450: In Vitro Kinetics and In Vitro—In Vivo Correlations , 2001 .

[11]  A. D. Rodrigues,et al.  Drug-drug interactions , 2001, Atkinson's Principles of Clinical Pharmacology.

[12]  I. Phillips,et al.  Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. , 2001, Biochemical pharmacology.

[13]  U. Hofmann,et al.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.

[14]  D. Greenblatt,et al.  CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[15]  C. Lindley,et al.  Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[16]  J. Beijnen,et al.  Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA). , 2000, Cancer treatment reviews.

[17]  S. Rodenhuis,et al.  Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens , 2000, Cancer Chemotherapy and Pharmacology.

[18]  M O Karlsson,et al.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. , 1999, British journal of clinical pharmacology.

[19]  S. Srivastava,et al.  Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. , 1999, Archives of biochemistry and biophysics.

[20]  D. Waxman,et al.  Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[21]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[22]  F. Appelbaum,et al.  Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients , 1998, Clinical pharmacology and therapeutics.

[23]  J. Peterse,et al.  Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement , 1998, The Lancet.

[24]  D. Flockhart,et al.  Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[25]  J. Wingard,et al.  Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Berry,et al.  A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies , 1996, Cancer Chemotherapy and Pharmacology.

[27]  S. Rodenhuis,et al.  High-dose chemotherapy regimens for solid tumors. , 1995, Cancer treatment reviews.

[28]  E. Wall.  High dose chemotherapy for solid tumors , 1995 .

[29]  R. Silverman.  Mechanism-based enzyme inactivators. , 1995, Methods in enzymology.

[30]  A. Deisseroth,et al.  A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. , 1994, Bone marrow transplantation.

[31]  G. F. Weber,et al.  Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. , 1993, Cancer research.

[32]  M. Dimopoulos,et al.  Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. , 1993, Blood.

[33]  P. Engstrom,et al.  Phase I/pharmacokinetic reevaluation of thioTEPA. , 1991, Cancer research.

[34]  D. Waxman,et al.  N,N',N''-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents. , 1991, Cancer research.

[35]  D. Waxman,et al.  Biotransformation of N,N',N''-triethylenethiophosphoramide: oxidative desulfuration to yield N,N',N''-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase. , 1990, Cancer research.

[36]  P. Beaune,et al.  Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. A. Neal,et al.  Inactivation of purified rat liver cytochrome P-450 during the metabolism of parathion (diethyl p-nitrophenyl phosphorothionate). , 1980, The Journal of biological chemistry.